At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
L-Carnitine helps to transport fatty acids to the mitochondria of the cell so it can be burned as fuel
in some cases a single burst of damage can drain up to 90 percent of a cells NAD+ pool
Thermogenesis The production of heat through metabolic processes
Oakland score showed highest specificity for safe discharge in lower GI bleeding by Doug Brunk In a prospective multicenter Canadian study, a score of 8 or less identified patients who could be discharged from the ED, though it was less sensitive than clinical judgment
P309+311: Call a POISON CENTER or doctor/physician if exposed or you feel unwell